Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer—A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer—A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib

Published:2019-04 Issue:2 Volume:19 Page:e283-e296
ISSN:1526-8209
Container-title:Clinical Breast Cancer
language:en
Short-container-title:Clinical Breast Cancer

Author:

Symonds Lynn,Linden Hannah,Gadi Vijayakrishna,Korde Larissa,Rodler Eve,Gralow Julie,Redman Mary,Baker Kelsey,Wu Quan (Vicky),Jenkins Isaac,Kurland Brenda,Garrison Mitchell,Smith Julie,Anderson Jeanne,Van Haelst Carol,Specht Jennifer

Funder

Genentech

Celegene

National Cancer Institute

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference43 articles.

1. Cancer statistics, 2018;Siegel;CA Cancer J Clin,2018

2. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications;Sørlie;USA Proc Natl Acad Sci,2001

3. Angiogenesis and antiangiogenesis in triple-negative breast cancer;Ribatti;Transl Oncol,2016

4. What is triple-negative breast cancer?;Irvin;Eur J Cancer,2008

5. Triple-negative breast cancer;Foulkes;N Engl J Med,2010

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Marine-derived EGFR inhibitors: novel compounds targeting breast cancer growth and drug resistance;Frontiers in Pharmacology;2024-05-01

2. Potential therapeutic targets of the JAK2/STAT3 signaling pathway in triple-negative breast cancer;Frontiers in Oncology;2024-04-18

3. PDZK1 suppresses TNBC development and sensitizes TNBC cells to erlotinib via the EGFR pathway;Cell Death & Disease;2024-04-12

4. Small molecule agents for triple negative breast cancer: Current status and future prospects;Translational Oncology;2024-03

5. A review of biological targets and therapeutic approaches in the management of triple-negative breast cancer;Journal of Advanced Research;2023-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3